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Abstract
MyD88, a Toll/interleukin-1 receptor homology (TIR) domain-containing adaptor protein, mediates signals from the Toll-like
receptors (TLR) or IL-1/IL-18 receptors to downstream kinases. In MyD88-dependent TLR4 signaling, the function of MyD88
is enhanced by another TIR domain-containing adaptor, Mal/TIRAP, which brings MyD88 to the plasma membrane and
promotes its interaction with the cytosolic region of TLR4. Hence, Mal is recognized as the ‘‘sorting adaptor’’ for MyD88. In
this study, a direct interaction between MyD88-TIR and another membrane-sorting adaptor, TRAM/TICAM-2, was
demonstrated in vitro. Cell-based assays including RNA interference experiments and TRAM deficient mice revealed that the
interplay between MyD88 and TRAM in cells is important in mediating IL-18 signal transduction. Live cell imaging further
demonstrated the co-localized accumulation of MyD88 and TRAM in the membrane regions in HEK293 cells. These findings
suggest that TRAM serves as the sorting adaptor for MyD88 in IL-18 signaling, which then facilitates the signal transduction.
The binding sites for TRAM are located in the TIR domain of MyD88 and actually overlap with the binding sites for Mal.
MyD88, the multifunctional signaling adaptor that works together with most of the TLR members and with the IL-1/IL-18
receptors, can interact with two distinct sorting adaptors, TRAM and Mal, in a conserved manner in a distinct context.
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Introduction
Toll-like receptors (TLRs) are representative innate immune
receptors that recognize pathogen-associated molecular patterns
(PAMPs). MyD88, a cytosolic adaptor protein, is involved in the
signaling pathways initiated by all of the reported TLRs with the
exception of TLR3 [1]. Usually, PAMPs first bind to the
extracellular domain of the TLRs, and the cytosolic region of
TLRs then interact with MyD88, which allows the signal to be
transmitted to the downstream kinase Interleukin (IL) -1 receptor
associated kinase 4 (IRAK4). The resulting activation of IRAK4
eventually leads to the activation of the transcription factors NF-
kB and AP-1 via conserved phosphorylation cascades [2]. MyD88
is composed of two functional domains: an N-terminal death
domain (DD) and a C-terminal Toll/Interleukin-1 receptor
homology (TIR) domain [3]. The DD is a protein interaction
module that is involved in a variety of cellular events. Similar to
the DD, the TIR domain also mediates protein-protein interac-
tions via homotypic TIR-TIR interactions. In contrast to the DD,
the TIR domain is almost exclusively found in the TLR related
cytosolic adaptors or in the cytosolic regions of the TLRs, IL-1 and
IL-18 receptors. Homotypic interactions of these protein in-
teraction modules play a pivotal role in transmitting the signals
downstream from the TLR; the TIR of MyD88 interacts with the
TIR of the TLRs, and the DD of MyD88 interacts with the DD of
IRAK4, which forms a large protein complex called the
Myddosome [4].
TLR4 signaling, the best characterized signaling pathway
among a dozen of known TLR pathways, is activated by
lipopolysaccharide (LPS) from gram-negative bacteria, and the
pathway plays a major role in endotoxin shock. Two modes of the
signaling have been described: the MyD88-dependent and
MyD88-independent pathways. In the MyD88-dependent TLR4
signal transduction pathway, another TIR domain-containing
adaptor protein, Mal (also called TIRAP), plays an important role.
Mal binds MyD88 via a homotypic TIR interaction and then
associates with the plasma membrane using its PIP2-binding
domain. Thus, Mal has been suggested to serve as a ‘‘sorting
adaptor’’ that recruits the ‘‘signaling adaptor’’, MyD88, to the
membrane region where the activated TLR4 resides [5]. Mal is
not an essential factor for the signaling because signal transduction
can occur even without Mal [6,7], but Mal can substantially
facilitate the signaling. A pair of TIR domain-containing adaptors,
TIR domain-containing adaptor inducing IFN-b (TRIF) and
TRIF-related adaptor molecule (TRAM), is known to play
important roles in the MyD88-independent TLR4-signaling
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the sorting adaptors, respectively. This pathway transmits signals
from TLR4 at early endosomes after the LPS-induced internal-
ization of TLR4 [8,9]. TRAM is known to deliver TRIF to the
endosomes via a specific region of the plasma membrane by using
its myristoylation site and polybasic region [10]. These findings
indicate that the specific combinations of the sorting and the
signaling TIR-containing adaptors define the specific signal
transduction pathways.
MyD88 is also involved in acquired immune responses because
it mediates the signals from the inflammatory cytokines IL-1 and
IL-18; ligand-activated IL-1/IL-18 receptors that subsequently
interact with MyD88 to trigger downstream protein kinase
cascades that eventually activate the transcription factors NF-kB
and AP-1 in a similar manner to TLR signaling. Although the
intracellular signaling pathway is similar to the MyD88-dependent
TLR4 pathway, the sorting-adaptor Mal is not involved [11]. As
mentioned above, TLR4 signaling is facilitated either by Mal
(MyD88-dependent pathway) or TRAM (MyD88-independent
pathway) in a pathway-dependent manner. The former mainly
localizes in PIP2 rich plasma membrane regions, while the latter is
found not only in the plasma membrane but also in the
internalized early endosomes that dispatch the signals. Thus,
different sorting adaptors recruit MyD88 to different membrane
regions and create distinct types of signal initiation complexes. In
contrast to TLR signals, IL-1/IL-18 signaling has not thus far
been thought to require such sorting adaptors. Interestingly,
Kagan et al. reported that an engineered MyD88 that is endowed
with PIP2 binding ability could rescue the LPS-TLR4 signaling in
mouse embryonic fibroblast (MEF) cells from MyD88 and Mal
double knockout mice, although it failed to rescue IL-1 signaling in
the cells [5]. This observation suggests that TLR4 and IL-1R are
located in distinct regions of the plasma membrane, which then
raises the hypothesis that unidentified sorting adaptors selectively
bring MyD88 to the appropriate membrane region to form signal
initiation complexes with activated IL-1 and IL-18 receptors.
In this study, we sought the sorting adaptor for IL-18 signaling
and discovered that TRAM is responsible for this function.
TRAM was demonstrated to directly interact with MyD88 in in
vitro binding experiments in which a homotypic TIR-TIR
interaction plays a vital role. The efforts to identify the interacting
sites in the MyD88-TIR interaction revealed that two surface sites
of MyD88-TIR are direct interfaces with TRAM-TIR. Interest-
ingly, these interaction sites overlap with the sites for Mal binding
[12]. Furthermore, cellular assays demonstrated the functional
involvement of TRAM in the IL-18 signal transduction, and
TRAM changed the localization of MyD88 from the cytosol to the
membranous regions. These new findings strongly suggest that
TRAM is the membrane-sorting adaptor for MyD88 in IL-18
signaling and plays a critical role in transmitting the signal. Thus,
the mechanism of signal initiation is more conserved between the
MyD88-dependent TLR4 pathway and IL-18 signaling than
previously thought.
Results
Binding of TRAM to MyD88
Five TIR containing adaptor proteins have been previously
identified: MyD88, Mal, TRIF, TRAM and SARM. Mal and
TRAM were reported to be the sorting adaptors for MyD88 and
TRIF, respectively [13]. Because a model structure of the TIR
domain of TRAM represents a substantially large negatively
charged surface area (Figure S1), while the TIR domain of MyD88
is covered by positive charge, we expected some interaction
between these two adaptor molecules. We thus further hypothe-
sized that TRAM also functions as the sorting adaptor for MyD88
in the IL-18 signaling pathway. To test these ideas, we first
examined the direct interaction between MyD88 and TRAM. As
both of the adaptors contain the TIR domain, which mediates the
protein-protein interaction generally via homomeric or hetero-
meric TIR-TIR interactions, the direct interaction between the
MyD88-TIR and the TRAM-TIR was examined with a GST-pull
down assay. The results indicated that the wild-type MyD88-TIR
directly bound the TRAM-TIR with a higher affinity than Mal,
while the interaction between MyD88-TIR and TLR1-TIR,
which had been shown not to bind the MyD88-TIR [14], was not
detected in this method (Figure 1A). We then examined the
interaction between MyD88 and TRAM in cells using a co-
immunoprecipitation analysis. When Myc-MyD88 and FLAG-
TRAM were co-expressed in HEK293 cells, the Myc-MyD88
constitutively associated with the FLAG-TRAM (Figure 2), which
is consistent with our GST-pull down assay. Strikingly, upon
stimulation of the cells with IL-18, the MyD88-TRAM complex
gradually dissociated over a 30- to 120-minute time course. The
HEK293 cells inherently express IL-18Ra (formerly called IL-
1Rrp), which is a necessary component for IL-18 signaling, but
lack IL-18Rb (formerly called IL-1AcPL). Thus, we additionally
co-expressed IL-18Rb in the cells for this experiment.
Binding of TRAM to IL-18 Receptors
For the activation of IL-18 signaling, the heterodimerization of
two IL-18 receptors, IL-18Ra and IL-18Rb, has been shown to be
required [15]. These receptors belong to the IL-1 receptor
superfamily and are thus structurally homologous to one another.
The extracellular region contains immunoglobulin (Ig)-like chains,
while the cytosolic region has a TIR domain that interacts with the
TIR domain of MyD88. To test the interaction of TRAM with
these IL-18 receptors, we performed GST pull-down assays using
the TIR domains of the IL-18 receptors and TRAM. The results
showed that the TIR domains from both IL-18Ra and IL-18Rb
directly bound the TRAM-TIR (Figure 1B).
Involvement of TRAM in IL-18 Signaling
After obtaining the evidence that TRAM interacts with MyD88
both in vitro and in cells, we then examined the possible
involvement of TRAM in IL-18 signaling. We knocked-down
the endogenous TRAM expression in HEK293 cells using siRNA
techniques and then performed NF-kB reporter assays for the IL-
18 signal transduction in the cells. The shRNA for the TRAM
expressing vector was generated based on the previously reported
target sequence [16]. When the expression of TRAM was
knocked-down (Figure 3A), NF-kB activity after IL-18 stimulation
was markedly decreased relative to the negative control experi-
ments that used scrambled shRNA (Figure 3B). This result
indicates that the knock-down of TRAM expression actually
impaired the IL-18 signal transduction. We confirmed the knock-
down effect of this shRNA sequence for TRAM via the LPS-
stimulated activation of IFN-b promoter, which is presumably due
to the suppression of the MyD88-independent TLR4 pathway
mediated by TRAM and TRIF (Figure 3C). The effect was similar
when compared to the results obtained from a dominant negative
form of TRAM (C117H). TRAM (C117H) showed an almost
complete shutdown of the LPS/TLR4/IFN-b signaling in the cells
(Figure 3D) and the decrease of the enhancement of NF-kB
activity induced by IL-18 (Figure 3E). To further confirm the
involvement of TRAM in the IL-18 signaling pathway, we
evaluated the cytokine production from helper type 1 differenti-
ated T (Th1) cells isolated from TRAM-deficient mice and
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only MyD88-deficient Th1 cells but also TRAM-deficient Th1
cells, significantly. And, IL-18 alone or IL-18 and IL-12 co-
stimulated TRAM-deficient Th1 cells produced significantly lower
IFN-c levels than those of wild-type Th1 cells (Figure 4).
IL-18 Modulates MyD88-TRAM Subcomplex in Human
Cells
Next, we further investigated whether MyD88 actually inter-
acted with TRAM in human HEK293T cells by live cell
fluoroimaging. When we transiently transfected a DsRed-TRAM
construct into HEK293T cells, the protein localized to the plasma
membrane region, which was consistent with a previous report
[10] (Figure 5A). In contrast, GFP-MyD88 was dominantly found
as foci in the cytosol in the cells expressing the protein; this has also
been shown by others [17] (Figure 5B). Strikingly, when
HEK293T cells were co-transfected with expression plasmids for
GFP-MyD88 and DsRed-TRAM, MyD88 proteins moderately
co-localized with TRAM in the membrane regions (Figure 5C).
These data strongly suggest that this transient interaction between
the two proteins dramatically altered the localization of GFP-
MyD88 from the cytosol to the membranes. Thus, TRAM both
bound and endowed MyD88 with membrane targeting properties
as has been previously demonstrated for Mal [5].
Identification of Important Amino Acid Residues of the
MyD88-TIR in IL-18 Signaling
Having established that MyD88 and TRAM directly interact
and that the interaction is critical in IL-18 signaling, we next
carried out experiments to identify the amino acid residues of
MyD88 that are important in this interaction. A cell-based
reporter assay system was utilized to examine various mutations in
Figure 1. Protein interaction assays. (A) GST pull-down assay investigating the direct interactions between the GST-MyD88-TIR and the TRAM-TIR
or TLR1-TIR. (B) GST pull-down assay between the GST-IL-18 receptor TIRs and TRAM-TIR.
doi:10.1371/journal.pone.0038423.g001
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shown in Figure 6A. An alanine substitution of any one of eight
residues (Arg196, Asp197, Lys214, Arg217, Lys238, Arg269,
Lys282 or Arg288) caused significantly reduced dominant negative
inhibitory effects on IL-18 signaling indicating that these residues
are involved in the signal transduction. These eight residues are
mapped on the protein structure of the MyD88-TIR (PDB code:
2z5v) (Figure 6B). In our previous experiments for LPS/TLR4
signaling using the same luciferase reporter system, three discrete
functional sites were found on the surface of the MyD88-TIR,
which we designated Site I, Site II, and Site III (Figure 6B) [12].
Five out of the eight residues, Arg196 (Site II), Asp197 (Site II),
Arg217 (Site I), Lys282 (Site III) or Arg288 (Site III) were
previously found to be important in the LPS/TLR4 signaling. We
then examined the direct binding of the representative mutants of
each functional sites of MyD88-TIR to the TRAM-TIR using
GST pull-down assays (Figure 6C). The results indicate that the
binding between the MyD88-TIR and TRAM-TIR is dependent
on Sites II and III because the alanine substitution of either
Arg196 or Arg288 resulted in decreased binding. Furthermore, the
interaction between the MyD88-TIR and TRAM-TIR was
completely abrogated when both Arg196 and Arg288 were
mutated. Additionally, co-immunoprecipitation assay also showed
the reduction of interaction between MyD88 R196A-R288A
mutant and TRAM (Figure 6D). In contrast, a Site I mutant,
R217A, did not show a significant decrease in binding affinity.
Overall, these interactions are very similar to those observed
between the MyD88-TIR and Mal-TIR [12], indicating that
TRAM and Mal share the same binding sites on MyD88-TIR.
Discussion
Involvement of TRAM in the IL-18 Pathway
Mal has been reported to function as the sorting adaptor in the
TLR4 signaling that brings MyD88 to the plasma membrane to
mediate the interactions between TLR4 and MyD88 [5]. Because
the IL-1 and IL-18 receptors also form signal initiation complexes
that contain MyD88, presumably at distinct membrane regions
from TLR4, the existence of currently unidentified sorting
adaptors that recruit MyD88 to specific membrane regions and
mediate the interactions between MyD88 and the IL-1/IL-18
receptors has been hypothesized [5]. Although several reports
have been published to date, the involvement of TRAM in IL-1
signaling remains controversial [16,18,19,20]. Using TRAM-
deficient mice, Yamamoto et al. showed that TRAM is not
involved in IL-1 signaling. Despite the homology between IL-1
and IL-18, the relationship between TRAM and IL-18 had not yet
been elucidated. In this study, we sought the sorting adaptor that
acts in IL-18 signaling and found that TRAM fulfils this role. It
was proposed that the electric potential is important for the
specific interactions between the TIR domain proteins [21].
According to the electric surface potentials of the TIR domain
structures, the TRAM-TIR and Mal-TIR both have a largely
acidic surface patch, while the MyD88-TIR has a largely basic
surface patch (Figure S1). Therefore we hypothesized that TRAM
interacts with MyD88 and works as the sorting adaptor that
recruits MyD88 in IL-18 signaling. In fact, TRAM has already
been reported as the sorting adaptor in the MyD88-independent
TLR4 pathway in which TRAM recruits TRIF to specific
membrane regions [10,22]. Nonetheless, in this work we obtained
multiple results that indicate that TRAM functions as the sorting
adaptor for IL-18 signals as we initially hypothesized. First,
TRAM bound to MyD88 in vitro and in cells (Figure 1A, 2, and
5C). Second, the intracellular TIR domains of IL-18 receptors also
bound to TRAM-TIR (Figure 1B). Finally, the shRNA knock-
down of TRAM expression and knock-out of TRAM caused
a significant decrease in the cellular response to IL-18 stimulation
(Figure 3 and 4). These findings strongly suggest that TRAM
functions as the sorting adaptor for MyD88 in IL-18 signaling. On
Figure 2. Assay of the interaction between MyD88 and TRAM in IL-18 signaling. (A) MyD88 and TRAM were co-expressed in HEK293T cells
along with IL-18Rb. IL-18 stimulation was carried out as indicated. MyD88 was immunoprecipitated using the Myc-tag antibody; co-
immunoprecipitated TRAM was also detected. (B) The opposite direction co-immunoprecipitation assay between MyD88 and TRAM. Myc-MyD88
was detected with immunoprecipitated FLAG-TRAM.
doi:10.1371/journal.pone.0038423.g002
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associated not only with TLR4 but also with the TLR2 and
TLR5 signaling pathways [23,24]. These findings suggest that the
conventionally accepted definition of the functions of the TIR
domain-containing adaptor proteins in the TLR and IL-1/18
signaling pathways should be reconsidered.
Time Dependent Change of the Interaction between
MyD88 and TRAM
A particularly interesting feature we observed in this study was
that the complex between Myc-MyD88 and FLAG-TRAM
expressed in HEK293T cells decreased after IL-18 stimulation
in a time-dependent manner (Figure 2). This observation suggests
that either the rearrangement of the signal initiation complexes or
the degradation of the components in the complexes is triggered
by the activation of the IL-18 signaling. A similar rearrangement
of the signal initiation complex has also been observed for the
TLR4 pathway in a previous report; upon activation of TLR4 by
LPS, TLR4 associated with MyD88 instantly, and the association
was lost within 15 min [25]. Thus, such transient interactions
between the receptors and adaptors and the subsequent loss of the
interaction may be common to both the TLR and the IL-18
pathways especially because they utilize many of the same
intracellular components. For the TLR4 complex, phosphoryla-
tion of TLR4 and Mal has been suggested to be involved in the
rearrangements [25,26]. TRAM has been shown to be phosphor-
ylated by Protein kinase C-e (PKC-e) upon stimulation by LPS,
and the phosphorylation has been implicated in regulating the
Figure 3. The knock-down effects of TRAM in IL-18 or LPS/TLR4 signaling. (A) RT-PCR of the TRAM mRNA knock-down in HEK293T cells by
the psiRNA-TICAM-2 but not by the nonspecific scrambled sequence coded psiRNA vector. ‘‘-‘‘ indicates cells not transfected with siRNA; ‘‘Actb’’
indicates the loading control (b-actin mRNA). (B–E) The effect of the knock-down of TRAM using shRNA or the dominant negative form of TRAM
(C117H) for the IL-18 or LPS induced NF-kB or IFN-b-promoter luciferase activity assay. The NF-kB and IFN-b-promoter activities with IL-18 or LPS
stimulation were significantly decreased in the IL-18Rb co-transfected HEK293T cells or HEK293-hTLR4-MD2-CD14 cells.
doi:10.1371/journal.pone.0038423.g003
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The membrane targeting of another myristoylated protein,
MARCKS, has been shown to be regulated by phosphorylation;
MARCKS is released from the plasma membrane upon the PKC
mediated phosphorylation of a serine near its myristoylation site
[28]. Similar to these examples, TRAM might be phosphorylated
in the IL-18-induced dissociation of the MyD88-TRAM complex
(Figure 2), although the mechanism underlying the dissociation
and its relevance to signal regulation remain to be elucidated.
The TRAM Interaction Sites of MyD88 are Similar to that
for Mal
According to our previous study [12], Sites I, II, and III on the
MyD88-TIR are functionally important in TLR4 signaling. These
sites also were recognized to be important in IL-18 signaling
(Figure 6A and 6B). We further demonstrated that Sites II and III
act as the TRAM binding sites of the MyD88 TIR domain
(Figure 6C), which overlap with the Mal binding sites [12]. The
two sites are distantly located from each other on opposite
molecular surfaces of the protein. Because of the molecular size of
the TIR domain, it is unlikely that both sites present a simultaneous
binding interface for a single TRAM-TIR to form a 1:1 complex.
It is more likely that each of these sites constitutes a distinct
interface for a different TRAM molecule in different binding
modes. Consistent with this hypothesis, a mutation of either
Arg196 or Arg288 leads to only moderate losses in the binding to
the TRAM-TIR in contrast to the fact that simultaneous
Figure 4. The IFN-c production from IL-18 and/or IL-12
stimulated Th1 cells from TRAM-deficient mice and MyD88
deficient mice. The IFN-c production levels were significantly reduced
in TRAM deficient mice and MyD88 deficient mice. The black bars show
the production levels from IL-18 and IL-12 co-stimulated Th1 cells, grey
bars show those from IL-18 solely stimulated Th1 cells, and the white
bars show those from no secondary stimulated Th1 cells.
doi:10.1371/journal.pone.0038423.g004
Figure 5. The localization of the MyD88 and TRAM complex in cells. (A–C) The localizations of the DsRed-TRAM (Red) and/or GFP-MyD88
(Green) in HEK293T cells. DAPI stained nuclei of HEK293T cells are shown in blue. Complexes of the DsRed fusion protein and GFP fusion protein are
shown in yellow.
doi:10.1371/journal.pone.0038423.g005
Interaction of MyD88 with TRAM
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38423mutations at both residues leads to a total loss of binding
(Figure 6C and 6D). With this dual binding mode via Sites II and
III, TRAM would be more efficient at recruiting MyD88 to
membrane regions. It should be noted that this dual binding mode
was also found in the binding between the MyD88-TIR and Mal-
TIR [12], which implies that this sort of multiple binding mode is
common to the TIR-containing adaptor proteins.
Additionally, in human, the deficiencies of TIR domain
containing adaptors, MyD88 and TRIF, have been recently
reported [29,30]. These deficiencies were categorized into the
innate immune defects. One of the mutations of MyD88, R196C,
is known to cause the severe pyogenic bacteria infection due to the
loss of interaction between TLR2, Mal and MyD88 [12].
According to the above-mentioned results, Arg196 is one of the
binding sites of MyD88 to TRAM. Therefore, the substitution of
Arg196 may abrogate not only an initial signaling of TLR
mediated by the interaction between Mal and MyD88 but also
a secondary enhancement of immune responses mediated by IL-
18 induced interaction between TRAM and MyD88 in T cells or
NK cells for etiology of human MyD88 deficiency syndrome.
In summary, we have established an unexpected connection
between TRAM and IL-18 signaling, which is mediated by a direct
TIR-TIR interaction between MyD88 and TRAM, and we
proposed that TRAM is the sorting adaptor for IL-18 signaling.
Based on the results obtained in this study, we present a schematic
model for signal initiation from activated IL-18 (Figure S2) that is
similar to the model for the LPS/TLR4 system.
Materials and Methods
Vector Preparations
The following recombinant protein expression cassettes were
subcloned into pGEX4T-1, pGEX5X-1 or pGEX5X-3 (GE
Healthcare, Buckinghamshire, England): IL-18, IL-1b, MyD88-
TIR (amino acid residues 148–296), TRAM-TIR (66–235),
TLR1-TIR (625–786), IL-18Ra-TIR (374–541), and IL-18Rb-
TIR (407–599). A cDNA encoding the MyD88 TIR domain
tagged at the N-terminus with a Myc-epitope was cloned into the
plasmid vector pcDNA3.1+ (Invitrogen, California, USA). IL-
18Rb and TRAM constructs tagged at the C-terminus with an
Figure 6. The interaction sites of MyD88 with TRAM. (A) Luciferase reporter gene activities with wild type and mutant types of the MyD88 TIR
domain after IL-18 stimulation. The black bars indicate that the residues show significant difference with wild type. (B) The functional assays of IL-18
signaling presented on the 3D structure of the TIR domain of MyD88. Results of the functional assays are mapped onto the molecular surface of the
MyD88 TIR domain. The amino acid residues judged to be significant by the luciferase assay are shown in red, while non-significant ones are shown in
light brown. The conserved motifs of boxes 1–3 (FDA of box1, VLPG of box2, FW of box3) are shown in blue. (C) Assay to study the binding of the wild
type or mutant TRAM TIR domain and MyD88 TIR domain. The representative alanine substitutions at Site II (R196A) or Site III (R288A) in MyD88
caused a reduced interaction with TRAM. The double alanine substituted mutant at Site II and Site III caused the complete abrogation of the
interaction with TRAM. (D) Immunoprecipitation assay between MyD88 wild or R196A–R288A mutant, and TRAM.
doi:10.1371/journal.pone.0038423.g006
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pcDNA3.1+. Mutants of TRAM and the TIR domain of
MyD88 were generated using the GeneEditor in vitro Site-Directed
Mutagenesis System (Promega, Wisconsin, USA). A pGL3-Basic
Vector (Promega) containing four kB binding sites, which was
used in the NF-kB luciferase reporter assay, and a Renilla
luciferase reporter vector used as an internal control in the assay
were gifts from Dr. Sewon Ki and Dr. Tetsuro Kokubo
(Yokohama City University). An IFN-b promoter region sequence
containing pGL4-Luc (Promega) was generated. A pAcGFP-C1-
MyD88 (GFP-MyD88) and a pDsRed-Monomer-N1-TRAM
(DsRed-TRAM) were also generated (Takara Bio, Shiga, Japan).
Protein Expression and GST Pull Down Assay
The TIR domain of the MyD88 wild type and mutants (R196A,
R217A, R288A, and R196A–R288A) and the IL-18 receptors (Ra
and Rb) were purified as GST (glutathione S-transferase) fusion
proteins according to methods previously described (1). The TIR
domain of human TRAM and TLR1 was also obtained by
a similar procedure as previously described for the MyD88-TIR.
These purified proteins were incubated with Glutathione Sephar-
ose 4B (GE Healthcare) for three hours at 4uC, and then these
resins were washed four times with wash buffer (20 mM potassium
phosphate buffer (pH 6.0), 100 mM KCl, 0.1 mM EDTA,
10 mM DTT, and 0.5% Triton X100), and then analyzed by
SDS polyacrylamide gel electrophoresis with Coomassie Brilliant
Blue staining. Experiments were performed in triplicate. The
mature form of human IL-18 and IL-1b were prepared using
E.Coli expression system according to previously reported
methods [15].
Cell Culture
HEK293-hTLR4-MD2-CD14 cells were purchased from In-
vivogen (California, USA), respectively. HEK293 cells were
cultured in Dulbecco’s Modified Eagle Medium (high glucose-
containing D-MEM, Invitrogen) supplemented with 10% heat-
inactivated fetal bovine serum (SIGMA-ALDRICH, Missouri,
USA), penicillin (100 U/mL) and streptomycin (100 mg/mL). All
cells were incubated at 37uC in a humidified atmosphere of 5%
CO2. The splenic pan T cells were isolated using Pan T Cell
Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany)
from the spleen of TRAM-deficient mice, MyD88-deficient mice
and background mice (C57BL/6) supplied by Oriental Bio Service
(Kyoto, Japan). The purified splenic T cells were incubated with or
without 2 ng/ml recombinant murine IL-12 (p70) (PEPRO-
TECH, New Jersey, USA) on BIOCOAT anti-mouse CD3 T-
cell activation plates (BD Biosciences, Massachusetts, USA) in
order to be differentiated into Th1 cells. After 4 days of culture, T
cells were washed and restimulated with 20 ng/ml recombinant
murine IL-18 (MBL, Nagoya, Japan) and/or 2 ng/ml recombi-
nant murine IL-12 (p70) on anti-mouse CD3 T-cell activation
plates for 24 hours. All animal experiments were carried out in
accordance with the NIH Guide for Care and Use of Laboratory
Animals. These cells were cultured in RPMI1640 media
(Invitrogen) supplemented with 10% heat-inactivated fetal bovine
serum, penicillin (100 U/mL) and streptomycin (100 mg/mL).
Co-immunoprecipitation Analysis
HEK293T cells in 100 mm plates were transfected with 5.0 mg
of pcDNA3.1+ IL-18Rb, 5.0 mg of pcDNA3.1+ Myc-tagged
MyD88 (full-length) wild or R196A–R288A mutant and/or
5.0 mg of pcDNA3.1+ FLAG-tagged TRAM (full-length) using
Lipofectamine 2000 (Invitrogen). After 18 hours, the culture media
were replaced. After 24 more hours, the cells were incubated with
or without IL-18 (10 ng/mL). These cells were washed with cold
PBS and harvested with cell lysis buffer (Tris-HCl buffer (pH 7.5)
with 10 mM NaCl, 10 mM EDTA, 0.5% Triton-X100, a protease
inhibitor cocktail (Roche Diagnostics, Mannheim, Germany), and
a phosphatase inhibitor cocktail (PIERCE, Illinois, USA). The
soluble cell lysates including 1000 mg protein were incubated with
5 mg of anti-Myc antibody (Invitrogen) or anti-FLAG M2
monoclonal antibody (SIGMA-ALDRICH) for 60 minutes;
50 ml of MultiMACS Protein G MicroBeads (Miltenyi Biotec)
that had been equilibrated with cell lysis buffer for 30 minutes at
4uC was then added to the lysates. After incubation, the immune
complexes were applied to the magnetic columns. The protein
complex samples were then solubilized with 16Laemmli sample
buffer after four washes with wash buffer. The samples were
analyzed by western blots using an anti-Myc antibody and an anti-
FLAG M2 monoclonal antibody.
Knock-down with shRNA or Dominant Negative Mutant
of TRAM
The shRNA expression vector psiRNA-h7SKgz-Scr (used as
a negative control because it contained a scrambled sequence) and
psiRNA-TICAM-2 were purchased from Invivogen. For the
reporter gene assays, HEK293T or HEK293-hTLR4-MD2-
CD14 cells were seeded at a density of 2.0610
5 cells/mL per
well in a 96-well plate. These cells were transfected with or without
pcDNA3.1+ IL-18Rb-AU1, NF-kB luciferase reporter vector, and
Renilla luciferase reporter vector with either the psiRNA-h7SKgz-
Scr or psiRNA-TICAM-2, pcDNA3.1+ TRAM-FLAG wild or
C117H mutant vector using Lipofectamine 2000. After 18 hours,
the culture media were replaced with fresh medium, and after an
additional 24-hour incubation, the culture media were replaced
with fresh medium containing recombinant human IL-18 (2.0, 5.0,
50.0 or 10.0 ng/mL) or LPSO127: B8, which is derived from E.
Coli strain (100 ng/mL) (SIGMA-ALDRICH), incubated for 6
hours. The luciferase reporter gene activities were analyzed using
a Dual-Luciferase Reporter Assay System (Promega). The
statistical significance of the differences in the luciferase activities
was determined using Dunnett’s multiple comparison test. The
statistical significance was assigned to be P,0.05.
RT-PCR
Total RNA from cells seeded in six-well plates was isolated with
ISOGEN (Nippon Gene, Toyama, Japan) according to the
manufacturer’s instructions. Reverse transcription was performed
with a 1st Strand cDNA Synthesis Kit (Roche Diagnostics)
according to the manufacturer’s instructions. The cDNA obtained
was used in PCR with Taq DNA polymerase (Toyobo, Osaka,
Japan) to determine the relative amount of TRAM mRNA.
ELISA
Culture supernatants in test tubes were centrifuged to remove
the cells and then stored at –80uC until analysis. The IFN-c
concentrations were measured using a Mouse IFN-c Quantikine
ELISA Kit (R&D Systems, Minnesota, USA). The statistical
significance of the differences in the cytokine productions between
the wild type cells and the TRAM or MyD88 deficient cells was
determined using two-way ANOVA with Bonferroni’s multiple
comparison test. The statistical significance was assigned to be
P,0.05.
Confocal Microscopy
For direct immunofluorescence, HEK293T cells co-transfected
GFP-MyD88 and DsRed-TRAM were washed in phosphate-
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phosphate-bufferedsaline.Cellswerethenpermeabilizedwith0.2%
Triton X-100 in phosphate buffered saline for 10 min at room
temperature.SamplesweremountedontocoverslipswithPro-Long
Gold Antifade reagent (Invitrogen) and were examined on a Zeiss
LSM5 EXCITER confocal microscope. All images were acquired
using an aplan-Apochrom at 63X with a 1.4-N.A. objective or at
100X with a 1.4-N.A. objective.
The Screening Method of Functional Residues of MyD88-
TIR in IL-18 Signaling
HEK293T cells were transfected with pcDNA3.1+ control
vector or pcDNA3.1+ myc-MyD88 TIR domain (wild-type or
mutants), pcDNA3.1+ IL-18Rb-AU1, NF-kB luciferase reporter
vector, and Renilla luciferase reporter vector using Lipofectamine
2000 according to the manufacturer’s instructions. These
transfectants were stimulated with recombinant human IL-18
(100 ng/mL) for 6 hours. The luciferase reporter gene activities
were also analyzed using a Dual-Luciferase Reporter Assay System
(Promega). The statistical significance of the differences was
determined using Dunnett’s multiple comparison test. The
statistical significance was assigned to be P,0.05.
Supporting Information
Figure S1 The surface electrostatic potential of the TIR
domain structure models from the TIR domain contain-
ing adaptor proteins. These structure models were predicted
from the template structure of the MyD88-TIR (PDB code: 2z5v)
using Discovery Studio 2.6 software (Accelrys). TRAM and MAL
have a largely acidic surface patch, while MyD88 has a largely
basic surface patch.
(TIFF)
Figure S2 A schematic model of the two distinct
regulation patterns in LPS induced TLR4 signaling and
IL-18 signaling. MyD88 is efficiently delivered to receptor
specific membrane regions by the membrane binding activities of
the two associated molecules of Mal or TRAM so that it can form
signal initiation complexes with activated TLR4 or IL-18
receptors. Upon stimulation, MyD88 starts to transmit signals
through interactions with activated TLR4 or IL-18R, which
triggers the phosphorylation cascade mediated by IRAKs and
TRAF6.
(TIFF)
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